Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban


Aslan A. N. , Sari C., Bastug S., Sari S. O. , AKÇAY M. , DURMAZ T. , ...More

BLOOD COAGULATION & FIBRINOLYSIS, vol.27, no.2, pp.226-227, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 2
  • Publication Date: 2016
  • Doi Number: 10.1097/mbc.0000000000000442
  • Title of Journal : BLOOD COAGULATION & FIBRINOLYSIS
  • Page Numbers: pp.226-227

Abstract

Rivaroxaban, a highly selective direct factor Xa inhibitor, is a new oral anticoagulant approved by the US Food and Drug Administration in November 2011 for stroke prophylaxis in patients with nonvalvular atrial fibrillation. Because of its efficacy and once-a-day dosing, it is commonly preferred in patients with nonvalvular atrial fibrillation and intolerance to warfarin in clinical practice. However, it can result in some adverse effects such as bleeding, rashes and liver injury. Here, we described a very rare adverse reaction of rivaroxaban, jaundice due to intrahepatic cholestasis, appeared in a 71-year-old male patient after taking rivaroxaban. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.